Finanzas de Sotera Health Co (SHC)SHCSotera Health Co

Sotera Health Company (SHC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sterigenics, accounting for 65.8% of total sales, equivalent to $211.57M. Other significant revenue streams include Nelson Labs and Nordion. Understanding this composition is critical for investors evaluating how SHC navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Sotera Health Company maintains a gross margin of 54.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 33.23%, while the net margin is 16.69%. These profitability ratios, combined with a Return on Equity (ROE) of 27.78%, provide a clear picture of how effectively SHC converts its operational activities into shareholder value.

In the context of the broader market, SHC competes directly with industry leaders such as STVN and GRAL. With a market capitalization of $5.20B, it holds a significant position in the sector. When comparing efficiency, SHC's gross margin of 54.44% stands against STVN's 29.51% and GRAL's -28.12%. Such benchmarking helps identify whether Sotera Health Company is trading at a premium or discount relative to its financial performance.

Sotera Health reported Q2 2026 revenue of $321.4 million, a 9.2% year-on-year increase, and an adjusted EPS of $0.26, exceeding expectations. The gross margin for Q2 was 54.44%, indicating strong profitability. However, the company has faced challenges with organic growth, averaging only 4.9% over the past two years, and has broken even in free cash flow over the last five years, which limits capital return to shareholders.